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Abstract
Background: Staphylococcus aureus is the most commonly isolated organism from the different clinical samples
in hospital. The emergence and dissemination of methicillin resistant Staphylococcus aureus (MRSA) and growing
resistance to non-beta-lactam antibiotics is making treatment of infections due to this organism increasingly
difficult.
Methods: This study was conducted to determine the frequency of Staphylococcus aureus isolated from different
clinical samples, rates of MRSA and full antibiotic susceptibility profiles. Clinical samples were cultured and
Staphylococcus aureus was identified using standard microbiological methods recommended by the American
Society for Microbiology (ASM). Methicillin resistance was confirmed using cefoxitin and oxacillin disks. Inducible
clindamycin resistance was identified using D-zone test.
Results: From the processed samples, 306 isolates of Staphylococcus aureus were recovered. All the isolates were
susceptible to vancomycin and teicoplanin. Methicillin resistance was observed in 43.1% of isolates while inducible
clindamycin resistance in 12.4% of the isolates.
Conclusions: The results of our study reveals that rates of resistance to commonly prescribed antibiotics in
Staphylococcus aureus clinical isolates is high. In particular, rate of methicillin resistance is alarming, prompting
concern on the rational use of antibiotics and vigilant laboratory-based surveillance of resistance rates in Nepal.
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Background
Staphylococcus aureus is one of the most common hu-
man pathogens capable of causing a wide range of infec-
tions [1]. Over the past several decades, it has been a
leading cause of both hospital and community-acquired
infections [2]. It is associated with a variety of clinical in-
fections including septicemia, pneumonia, wound sepsis,
septic arthritis, osteomyelitis and post-surgical toxic
shock syndrome with substantial rates of morbidity and
mortality [3-6].
Increasing rates of antimicrobial resistance, often re-
lated to extensive use of antimicrobials, is resulting in
fewer treatment options for bacterial infections. This
problem is being identified across many different micro-
organisms, such as Pseudomonas spp. and Enterococcus
spp [7]. Concerningly, rates of resistance to conventional
antibiotics in Staphylococcus aureus has increased to
high levels in some hospitals [8,9]. The incidence of
community-acquired and hospital acquired Staphylococ-
cus aureus infections has been rising with increasing
emergence of drug-resistant strains called methicillin re-
sistant Staphylococcus aureus (MRSA) [10-14]. MRSA
now represents a global problem. Ever since its isolation,
MRSA has emerged as one of the most common causes
of hospital acquired infection and continues to remain
as an important factor contributing to failure of manage-
ment [15]. MRSA is frequently resistant to most of the
commonly used antimicrobial agents including the ami-
noglycosides, macrolides, chloramphenicol, tetracycline
and fluoroquinolones [16]. In addition, MRSA strains
should be considered to be resistant to all cephalosporins,
cephems and other beta-lactams (such as ampicillin-
sulbactam, amoxicillin-clavulanic acid, ticarcillin-clavulanic
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acid, piperacillin-tazobactam and the carbapenems) re-
gardless of the in vitro test results obtained with those
agents [17].
The objectives of this study, therefore, were to identify
strains of Staphylococcus aureus from clinical samples
and determine antimicrobial susceptibility profiles of
these isolates.
Methods
A retrospective study was conducted from December 2010
to December 2012 at Chitwan Medical College Teaching
Hospital (a 600 bed teaching hospital), Chitwan, Nepal.
Patients were identified and data were extracted using
the hospital information and support system.
Sample collection
The samples were collected in sterile containers by cli-
nicians using aseptic technique and transported to the
laboratory without delay. All samples were processed
immediately.
Culture and bacterial identification
For the isolation and identification of Staphylococcus
aureus, several media used were brain heart infusion
(BHI) broth (for blood sample), blood agar (BA), choc-
olate agar (CHA), MacConkey agar (MA), DNase agar
and mannitol salt agar (HiMedia Laboratories Pvt. Lim-
ited, India) and the tests used were catalase and coagulase.
The collected samples were inoculated onto different cul-
ture media. The CHA plates were incubated in a CO2 in-
cubator (10% CO2) at 37°C for 24 hours. The BA and MA
plates were incubated at 37°C for 24 hours in an aerobic
atmosphere. Staphylococcus aureus was identified by
standard microbiological techniques [18]. A purity plate
was employed to ensure that the inoculum used for the
biochemical tests was pure.
Antibiotic susceptibility testing
Antibiotic susceptibility tests of the Staphylococcus aureus
isolates were performed by modified Kirby-Bauer disk
diffusion method in compliance with Clinical and Labora-
tory Standards Institute (CLSI) guidelines using Mueller-
Hinton agar standard media. The inhibition zone standards
for antimicrobial susceptibility were considered from tables
for interpretative zone diameters of CLSI [19]. Antibiotic
disks (HiMedia Laboratories, Pvt. Limited, India) used
were: penicillin G (10U), ciprofloxacin (5 μg), erythro-
mycin (15 μg), co-trimoxazole (25 μg), gentamicin (10 μg),
amikacin (30 μg), cephalexin (30 μg), ceftriaxone 30 μg),
cefoxitin (30 μg), oxacillin (1 μg), vancomycin (30 μg),
clindamycin (2 μg) and teicoplanin (30 μg). For the
identification of MRSA strains, cefoxitin and oxacillin
disks were used.
Identification of methicillin resistant Staphylococcus
aureus (MRSA) strains
Methicillin resistant Staphylococcus aureus (MRSA) was
identified by using oxacillin (1 μg) and cefoxitin (30 μg)
disks. Plates were incubated at 35°C. Plates containing
oxacillin disk were read following a 24 hour incubation
period. The diameter of the zone of inhibition (ZOI) of
growth was recorded and interpreted as susceptible or re-
sistant according to the criteria of CLSI. Staphylococcus
aureus isolates were deemed methicillin resistant when
the ZOI was ≤10 mm with the oxacillin disk or ≤21 mm
with the cefoxitin disk [20].
Identification of inducible clindamycin resistant strains
Inducible macrolide-lincosamide-streptogramin B (iMLSB)
resistance was detected in Staphylococcus aureus by Disk
approximation test placing a 2 μg clindamycin disk 15 mm
away from the edge of a 15 μg erythromycin disk on a
MHA plate. Following incubation, organisms that showed
flattening of the clindamycin zone adjacent to the erythro-
mycin disk (referred to as a “D” zone) were considered to
exhibit inducible clindamycin resistance [20].
Staphylococcus aureus ATCC 25923 was used as a con-
trol organism for antibiotic sensitivity testing. For MRSA
detection, Staphylococcus aureus ATCC 25923 and
ATCC 43300 were used as negative and positive con-
trols respectively.
Ethical aspects
The samples used in this study were from routine clin-
ical specimens. Because acquiring the samples did not
involve direct patient contact and did not interrupt rou-
tine clinical care, consent was not required. Permission




A total of 15718 samples (blood 7200, urine 7170, spu-
tum 860 and pus 488) were processed from both in-
patients and out-patients. Of 306 isolates of Staphylococ-
cus aureus (175 from female patients and 131 from male
patients), 120 (39.2%), 83 (27.1%), 63 (20.6%) and 40
(13.1%) were obtained from blood, pus, urine and spu-
tum respectively. Among the processed samples the
highest positivity rate was found in pus sample (17.0%)
followed by sputum (4.7%), blood (1.7%) and urine
(0.9%). The age distribution of the isolates is shown in
Table 1.
Antimicrobial susceptibility testing
The antibiogram of the Staphylococcus aureus isolates is
shown in Table 2. Interestingly, only vancomycin and
teicoplanin retained 100% susceptibility. Almost all isolates
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(94.7%) were resistant to penicillin, and most of them were
resistant to other commonly used antibiotics. 43.1% of the
isolates were resistant to methicillin by cefoxitin method,
and 39.2% were resistant to oxacillin. Of the 100 isolates
exhibiting erythromycin resistance, 38 (12.4%) were found
to have inducible clindamycin resistance by D-zone test.
Discussion
Staphylococcus aureus gain access to the epidermis through
cracks in the skin, abrasions, cuts, burns, surgical incisions
and intravenous catheters causing wide spectrum of in-
fections, from localized skin lesions such as abscesses,
folliculitis to deep seated infections. In the present
study, of 306 isolates of Staphylococcus aureus, 27%
were from pus sample, which signifies their important
role in abscess formation.
Antimicrobial resistance has been noticed as one of the
paramount microbial threats of the twenty-first century
[21]. The multidrug resistance to most of the antibiotics
used in infections caused by staphylococci is an increasing
problem. The emergence of methicillin resistance among
Staphylococcus aureus strains led to difficulties in the
treatment of infections caused by this organism [22].
Therefore, surveillance on the antimicrobial susceptibility
patterns of Staphylococcus aureus is of utmost importance
in understanding new and emerging resistance trends
as well as in the management of both hospital and
community-acquired infections.
This study demonstrated that overall rates of susceptibi-
lity to commonly prescribed antibiotics in Staphylococcus
aureus isolates were below 70%, with the exception of clin-
damycin, amikacin, teicoplanin, and vancomycin. Despite
the considerable progress in antimicrobial therapy, re-
sistance in Gram-positive pathogens continues to in-
crease, mainly in relation to the drugs commonly used in
medical practice. A high proportion of isolates (94.7%)
were resistant to penicillin in this study. This was ex-
pected as it has been recognized that only a small propor-
tion of the Staphylococcus aurues lineages do not produce
beta-lactamases [23-26].
Erythromycin has been used extensively for the treat-
ment of both minor and more serious staphylococcal in-
fections. As a consequence, its role today is increasingly
limited due to increasing resistance, which poses a great
therapeutic challenge. One third (32.7%) of our isolates
were resistant to erythromycin, compared to previous
similar studies in Nepal which have round resistance rates
of 7.1% in 2010, 11% in 2011, 63.6% in 2013 [24,27,25].
Similarly, trimethoprim-sulfamethoxazole (co-trimoxa-
zole) can be an alternative treatment choice, particularly
for non-multi-resistant MRSA infections, although emer-
gence of resistance has been previously observed. This
may be due to excessive use of this drug for many other
infections and over-the-counter availability of antimi-
crobials in the developing world for the treatment of
many other infections. 81.7% of our isolates were resist-
ant to co-trimoxazole, compared with 42.96% in 2009
[28], 12.5% in 2010 [26], 64% in 2011 [27], and 72.7% in
2013 [25] in Nepal.
While ciprofloxacin is predominantly a Gram-negative
drug, it does have activity against Staphylococcus aureus.
As a consequence of low cost and easy availability, there
has been indiscriminate use of ciprofloxacin in Nepal.
We identified resistance rate of 63.7%, much higher than
previous studies (26% in 2009 [23], 12% in 2011 [27]).
The same trend is seen with gentamicin, with 60.4% of
our isolates being resistant compared with 46.98% in
2009 [28], 32.73% in 2010 [26], 11% in 2011 [27], and
54.5% in 2013 [25]. Fortunately, rate of resistance to
amikacin remains low.
All of our isolates had retained susceptibility to vanco-
mycin and teicoplanin, consistent with previous studies
[23,25-27,29], confirming that glycopeptides should be
used as empiric therapy for serious staphylococcal infec-
tions while waiting for susceptibility testing results to
come through [30]. This is likely related to low usage of
Table 1 Distribution of clinical isolates of Staphylococcus
aureus according to the age of patients (n = 306)










Table 2 Antibiogram of Staphylococcus aureus (n = 306)
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these agents in Nepal due to high cost. Concerningly,
however, lineages with increased resistance to teicopla-
nin have been observed overseas [31-34].
Clindamycin is one of the drugs of choice in MRSA in-
fections. Macrolide-resistant isolates of Staphylococcus
aureus may have constitutive or inducible resistance to
clindamycin (due to methylation of the 23S rRNA
encoded by the erm gene also referred to as MLSB i.e.,
Macrolide, Lincosamide and type B Streptogramin re-
sistance) or may be resistant only to macrolides (due to
efflux mechanism encoded by the msrA gene) [20]. As
the presence of an erm gene encoding for inducible resist-
ance may result in treatment failure [35], it is important to
perform its testing. We found 38 (12.4%) D-test positive
isolates, indicating inducible resistance to clindamycin.
Today the concern of MRSA has reached the pinnacle.
It is noteworthy that MRSA can cause both community
and hospital acquired infections. Prior antibiotic use is
the most common risk factor for colonization and infec-
tion with MRSA. In our study, 43.1% of Staphylococcus
aureus isolates were found to be MRSA which is higher
as compared to other studies conducted in Nepal. The
incidence of MRSA was reported to be 20% in 2001 [36],
15.4% in 2005 [37], 26.14% in 2008 [29], 39.6% in 2010
[26] and 42.4% in 2013 [25] in Nepal.
Two different methods were employed for the detec-
tion of MRSA. The cefoxitin disk method detected 132
(43.1%) MRSA cases while the oxacillin disk method
missed 12 cases and detected only 120 (39.2%) Staphylo-
coccus aureus as MRSA. According to CLSI [20], the
cefoxitin disk test is comparable to the oxacillin disk test
for the prediction of mecA-mediated resistance to oxa-
cillin. The cefoxitin disk test is easier to read and thus is
the preferred method. Besides, cefoxitin is an inducer of
the mecA gene.
There are a number of factors contributing to increas-
ing rates of resistance in Staphylococcus aureus in Nepal.
Firstly, regulation of antibiotics is poor with their easy
and over the counter availability without prescription.
Some health care workers and pharmacists are often
paid incentives by the pharmaceutical companies to pre-
scribe or sell unnecessary antibiotics. Medical practice
by unqualified personnel, who often prescribe unneces-
sary antibiotics, is yet other common problem in Nepal.
Locally produced antibiotics are of questionable quality;
and compliance of the patients is also often poor. Many
antibiotics are prescribed without culture and sensitivity
due to lack of laboratory facilities in most of the areas.
Moreover, infection control policies are yet to be insti-
tuted properly in most of the hospitals and medical in-
stitutions of Nepal.
Thus, regular surveillance of hospital associated infec-
tions and antibiotic sensitivity pattern of MRSA; and for-
mulation of definite antibiotic policy may be helpful for
reducing the incidence of MRSA infection. Furthermore,
healthcare workers should be trained to control hospital
infection and infection control program should be con-
ducted effectively in all health care centers.
Conclusion
This report demonstrates high rates of MRSA and resist-
ance to other drugs in Staphylococcus aureus in our hos-
pital. There is a need for longitudinal surveillance of
MRSA and its antimicrobial susceptibility profile in
Nepal. We recommend effective implementation of hos-
pital infection control and antibiotic policies to control
antibiotic resistance in Staphylococcus aureus.
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